DelveInsight’s “Facioscapulohumeral Muscular Dystrophy (FSHD) Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of the FSHD, historical and forecasted epidemiology, as well as the FSHD market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
To Know in detail about the FSHD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Facioscapulohumeral Muscular Dystrophy Market Forecast
Some of the key facts of the FSHD Market Report:
- The FSHD market size was valued at approximately USD 600 million in 2025 across the 7MM (United States, EU4, United Kingdom, and Japan) and is projected to expand significantly by 2036 with a CAGR of ~15% during the forecast period 2026-2036.
- FSHD is the second most common adult-onset muscular dystrophy worldwide, characterized by progressive weakness in the facial, shoulder-girdle, and upper-arm muscles, with involvement extending to abdominal, lower-limb, and pelvic-girdle muscles.
- In 2025, among the 7MM, the US accounted for approximately 45% of total FSHD cases, which are expected to increase further by 2036, with approximately 79,700 prevalent cases in the US in 2025.
- About 80% of people with the FSHD genotype will develop symptoms, while 20% who test positive are asymptomatic. In FSHD1, a child of an affected parent has a 50% chance of inheriting the condition.
- Key FSHD Companies: Novartis (Avidity Biosciences), Arrowhead Pharmaceuticals, Scholar Rock, Epicrispr Biotechnologies, Restem, Modalis Therapeutics, and others.
- The FSHD pipeline includes promising emerging therapies: Delpacibart braxlosiran (del-brax), ARO-DUX4, Apitegromab, EPI-321, Restem-L, MDL-103, and others targeting the root cause of the disease.
- In March 2026, Roche discontinued clinical development of GYM329 for FSHD. In February 2026, Novartis completed the acquisition of Avidity Biosciences, strengthening its late-stage neuroscience pipeline.
- In January 2026, Epicrispr reported early clinical data from its first-in-human study of EPI-321, an epigenetic therapy for FSHD. In August 2025, the first patient was dosed in the global clinical trial.
- Delpacibart braxlosiran (del-brax) is currently in development with topline data from the FORTITUDE biomarker cohort expected in Q2 2026, and Phase III readout and global regulatory submissions anticipated in 2028.
- FSHD is one of the most common myopathies, involving over 870,000 people worldwide, with the prevalence estimated at approximately 1 in 8,000 to 1 in 15,000 in the US.
- There are currently no approved disease-modifying therapies for FSHD. Treatment focuses on symptomatic and supportive care including physical therapy, exercise, pain management, and in selected cases, surgical interventions.
- About 20% of FSHD patients eventually lose the ability to stand and walk, becoming reliant on a wheelchair for mobility, highlighting the significant disease burden and unmet medical needs.
- The FSHD market is anticipated to expand significantly due to improved diagnosis, increasing awareness, rising healthcare investment, and advancements in genetic, RNA-based, and gene-editing therapies targeting DUX4 expression.
- The FSHD market is expected to surge due to the disease’s increasing prevalence, enhanced diagnostic capabilities, and the launch of emerging therapies during the forecast period.
Facioscapulohumeral Muscular Dystrophy (FSHD) Overview
Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic muscle disorder characterized by progressive weakening of the facial, shoulder, and upper arm muscles. It is one of the most common forms of muscular dystrophy, with symptoms often beginning in adolescence or early adulthood, though early-onset cases can occur in childhood. FSHD is caused by genetic changes that lead to inappropriate activation of the DUX4 gene, resulting in muscle damage over time. The disease presents with a characteristic “stuttering progression pattern” marked by periods of stability followed by rapid decline. While there is currently no cure, supportive therapies such as physical therapy and assistive devices help manage symptoms and improve quality of life.
Get a Free sample for the FSHD Market Report https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Facioscapulohumeral Muscular Dystrophy (FSHD) Epidemiology
The FSHD epidemiology section provides insights about the historical and current FSHD patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the FSHD market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings from FSHD Epidemiological Analysis:
- In 2025, there were nearly 16,000 cases of FSHD1 in the 7MM, with FSHD1 accounting for approximately 95% of cases in the US, significantly higher than FSHD2.
- The prevalence of FSHD is estimated at approximately 1 in 8,000 to 1 in 15,000 in the US and about 1 in 20,000 in both Italy and the UK.
- FSHD is one of the most common myopathies, involving over 870,000 people worldwide and over 20 FSHD national registries.
- In 2025, among the age-specific cases of FSHD in the 7MM, the highest cases were in patients aged 50 years and above, while the lowest were in those below 18.
- In the US, the highest proportion of FSHD cases is observed in the most severe category (severity score 7 to 10) at approximately 40%, followed by moderate severity (4 to 6).
- In the US, FSHD cases are distributed almost equally between males and females, with a slight predominance in males compared to females.
Download the report to understand which factors are driving FSHD epidemiology trends @ FSHD Epidemiology Forecast
FSHD Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of potential FSHD drugs expected to be launched in the market during the forecast period 2026-2036. The analysis covers FSHD market uptake by drugs, patient uptake by therapies, and sales of each drug.
The current market uptake in FSHD remains limited, as there are no approved disease-modifying therapies, and treatment primarily relies on symptomatic management such as physical therapy, pain control, and supportive care. However, the emergence of gene-targeting, RNA-based, and regenerative therapies is expected to gradually improve uptake, with future adoption likely to increase as these innovative treatments demonstrate clinical efficacy and receive regulatory approval.
The FSHD report provides insights into different therapeutic candidates in Phase I-III clinical development. It also analyzes FSHD companies involved in developing targeted therapeutics.
FSHD Pipeline Development Activities:
The FSHD report covers detailed information of collaborations, acquisitions, mergers, licensing, patent details, and other information for FSHD emerging therapies, highlighting the robust development ecosystem.
FSHD Key Therapies and Companies
FSHD Key Therapies:
- Delpacibart braxlosiran (del-brax) – Novartis (Avidity Biosciences): DUX4-targeting therapy in Phase III with anticipated launch in 2029
- ARO-DUX4 – Arrowhead Pharmaceuticals: RNA interference conjugate targeting DUX4 gene in Phase II
- EPI-321 – Epicrispr Biotechnologies: First epigenetic editing therapy in Phase I/II, the first and only to receive IND authorization
- Apitegromab – Scholar Rock: Selective anti-latent myostatin monoclonal antibody in Phase II
- Restem-L – Restem: Umbilical cord-derived progenitor cells in Phase I/II
- MDL-103 – Modalis Therapeutics: Preclinical stage therapy
FSHD Key Companies: Novartis (Avidity Biosciences), Arrowhead Pharmaceuticals, Scholar Rock, Epicrispr Biotechnologies, Restem, Modalis Therapeutics, and others.
Discover more about emerging therapies set to transform the FSHD market @ FSHD Treatment Market
FSHD Market Drivers
- Rising FSHD prevalence with improved diagnostic capabilities
- Increasing disease awareness among patients and healthcare providers
- Rising opportunities in targeted and genetic therapies
- Emerging gene-targeting and RNA-based approaches
- Better understanding of disease pathogenesis targeting DUX4 mechanisms
- Rising healthcare investment and incremental spending
- Development of first-in-class disease-modifying therapies
FSHD Market Barriers
- Lack of approved disease-modifying therapies
- Need for earlier and more accurate diagnostic methods
- Limited treatment options for muscle weakness and functional impairment
- High cost of emerging therapies limiting market access
- Inadequate multidisciplinary care and long-term patient support
- Challenges in pain and disability management
Scope of the FSHD Market Report
- Study Period: 2022-2036
- Forecast Period: 2026-2036
- Coverage: 7MM [North America: The US; Europe: Germany, France, Italy, Spain and the UK; Asia-Pacific: Japan]
- FSHD Market CAGR: ~15% (2026-2036)
- Key FSHD Companies: Novartis (Avidity Biosciences), Arrowhead Pharmaceuticals, Scholar Rock, Epicrispr Biotechnologies, Restem, Modalis Therapeutics, and others
- FSHD Therapeutic Assessment: Current marketed and emerging therapies across Phase I-III
- FSHD Market Dynamics: Market drivers and market barriers
- Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, Porter’s five forces, Market entry strategies
- FSHD Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Contact Us
Kanishk
